Theseus Pharmaceuticals Inc. (NASDAQ:THRX) does about 181.22K shares in volume on a normal day but saw 2553528 shares change hands in Monday trading. The company now has a market cap of 454.30M USD. Its current market price is $11.00, marking a decrease of -0.45% compared to the previous close of $11.05. The 52 week high reached by this stock is $15.21 whilst the lowest price level in 52 weeks is $4.01. The script in recent trading has seen the stock touch a high of $11.56 and a low of $10.31.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Theseus Pharmaceuticals Inc. (THRX) has a 20-day trading average at $7.94 and the current price is -27.68% off the 52-week high compared with 174.31% distance from its 52-week low. The 50-day simple moving average of the closing price is $6.89 and its 200-day simple moving average is $7.11. If we look at the stock’s price movements over the week, volatility stands at 17.07%, which decreases to 11.93% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 70.27 to suggest the stock is overbought.
6 analysts observing the Theseus Pharmaceuticals Inc. (THRX) stock have set the 12-month price targets for the company’s shares at between $18.00 and $24.00. The consensus objective for the share price is $21.67, suggesting that the stock has a potential upside of 49.24% over the period. The median price target is 50.0% away from the current levels at $22.00.
FactSet Research has provided data showing that 6 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 5 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 14, 2022 when Needham initiated the stock to “Buy” and issued a price target of $22. Wedbush initiated its price target at $24.
The current price level is 43.54%, 61.85%, and 54.40% away from its SMA20, SMA50, and SMA200 respectively, with the THRX price moving below the 50-day SMA on January 23. Theseus Pharmaceuticals Inc. (THRX) stock is up 14.58% over the week and 104.08% over the past month. Its price is 120.88% year-to-date and 11.00% over the past year.
The company’s next earnings report is expected on 05/11/2023, with forecasts estimating quarterly EPS at -$0.34 and -$1.29 for whole year. THRX’s earnings per share are forecast to grow by 54.60% this year and -40.30% over next year.
Its 12-month price target is $22.00. To reach the target analysts have set, the stock logically needs to grow 49.24 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $18.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $24.00.
Outstanding shares total 38.59M with insiders holding 1.56% of the shares and institutional holders owning 89.68% of the company’s common stock. The company has a return on equity of -19.60%. Price to book ratio is 1.94.
Fidelity Select Port – Biotechno isn’t the only investment manager who changed stakes and is followed by T Rowe Price Health Sciences Fund, which sold off 69580.0 shares to end up with 1,009,115 shares worth $5.03 million.
